The use of activated clotting times to monitor heparin therapy during and after interventional procedures.
Use of the activated clotting time (ACT) was recommended in the mid 1970s to guide administration and reversal of heparin during cardiopulmonary bypass. As the applications of cardiopulmonary bypass spread, so too did the need for more efficient techniques to assess coagulation status. This led to the development of automated ACT measurements. Today, the importance of coagulation and anticoagulation has been further highlighted by recent advances in the field of interventional cardiology. More and more cardiologists are using in-laboratory bedside coagulation monitoring to assess heparin requirements during interventional procedures such as percutaneous transluminal coronary angioplasty (PTCA). This review focuses on the development of anticoagulation monitoring and provides historic information on the clinical use of heparin. The application of ACTs in the catheterization laboratory and in other clinical situations is discussed, along with alternative methods for bedside assessment of coagulation status. No definite guidelines have been established for ACT monitoring during invasive intravascular procedures; thus its role continues to be refined. In the meantime, the ACT appears to be an extremely useful method for monitoring heparin therapy and the adequacy of anticoagulation.
Bowers
J
J
Texas Heart Institute, St. Luke's Episcopal Hospital, Houston 77225.
Ferguson
J J
JJ
D015906:Angioplasty, Balloon, Coronary; D006328:Cardiac Catheterization; D002315:Cardiopulmonary Bypass; D016903:Drug Monitoring / Q000295:instrumentation / Q000379:methods; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D014914:Whole Blood Coagulation Time
D006493:Heparin